TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy